Profile
| Metric | Value |
|---|---|
| Full Name | Terns Pharmaceuticals, Inc. |
| Ticker | NASDAQ: TERN |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Country | United States |
| IPO | |
| Indexes | Not included |
| Website | ternspharma.com |
| Employees | 59 |
Key Metrics
| Metric | Date | Value |
|---|---|---|
| Price | $40.00 | |
| Price, 1D Change | +4.38% | |
| Market Cap | $4B | |
| - | ||
| PE Ratio | - | |
| Beta | 1.08 | |
| Revenue | $0 | |
| Revenue, 1Y Change | 0.00% | |
| EPS | -$1.12 | |
| EPS, 1Y Change | +11.72% |
Chart
Add series to chart(max: 6)
Series
SUGGESTED SERIES
Events
| Metric | Date | Value |
|---|---|---|
| Next Earnings | N/A | |
| Last Qtr. Earnings | ||
| Last Ann. Earnings | ||
| Last Ex-Dividend | N/A | N/A |
| Next Ex-Dividend | N/A | N/A |
| Last Split | N/A | N/A |
| Next Split | N/A | N/A |
| Last Ticker Change | N/A | N/A |
| Next Ticker Change | N/A | N/A |
🔒 Log In To Unlock Full Data
Estimates
| Metric | Date | Value |
|---|---|---|
| EPS | -$1.12 | |
| EPS Estimate | N/A | -$1.09 |
| EPS Est. Change | N/A | +2.12% |
| Revenue | $0.00 | |
| Revenue Estimate | N/A | - |
| Revenue Est. Change | N/A | - |
| Current Price | $40.00 | |
| Price Target | - | $56.00 |
| Price Tgt. Change | - | +40.00% |
🔒 Log In To Unlock Full Data
EPS
| Year | Estimate | Reported | Surprise / Exp. |
|---|---|---|---|
| -$1.33 | -$1.27 | +4.82% | |
| -$1.20 | -$1.12 | +6.61% | |
| -$1.09 | N/A | +2.12% | |
| -$1.22 | N/A | -9.06% |
Revenue
| Year | Estimate | Reported | Surprise / Exp. |
|---|---|---|---|
| - | $0.00 | - | |
| - | $0.00 | - | |
| - | N/A | - | |
| - | N/A | - |
🔒 Log In To Unlock Full Data
Performance
| Metric | Date | Value |
|---|---|---|
| Price, 1Y | +610.48% | |
| Price, 3Y | +338.12% | |
| Market Cap, 1Y | +634.56% | |
| Market Cap, 3Y | +634.61% | |
| Revenue, 1Y | 0.00% | |
| Revenue, 3Y | -100.00% | |
| EPS, 1Y | +11.72% | |
| EPS, 3Y | +43.70% |
🔒 Log In To Unlock Full Data
Technical Indicators
| Metric | Date | Value |
|---|---|---|
| Current Price | $40.00 | |
| SMA 200 | $11.29 | |
| SMA 200 vs Price | -71.78% | |
| SMA 50 | $29.79 | |
| SMA 50 vs Price | -25.54% | |
| Beta | 1.08 | |
| ATR | $2.40 | |
| 14-Day RSI | 59.37 | |
| 10-Day Volatility | 36.46% | |
| 1-Year Volatility | 109.44% |
Dividends
| Metric | Date | Value |
|---|---|---|
| N/A | - | |
| Upcoming | N/A | N/A |
| - | ||
| - | ||
| Dividends Paid | $0.00 | |
| Payout Ratio | 0.00% |
🔒 Log In To Unlock Full Data
Income & Profitability
| Metric | Date | Value |
|---|---|---|
| Revenue | $0.00 | |
| EPS | -$1.12 | |
| Gross Profit | -$896.00K | |
| Gross Margin | - | |
| Operating Profit | -$101.87M | |
| Operating Margin | - | |
| Net Income | -$88.85M | |
| Net Margin | - | |
| EBITDA | -$100.98M |
🔒 Log In To Unlock Full Data
Financial Health
| Metric | Date | Value |
|---|---|---|
| Debt To Equity | 0.00 | |
| Current Ratio | 23.14 | |
| Quick Ratio | 23.14 | |
| - | ||
| - | ||
| Altman Z-Score | 118.31 |
Valuations
| Metric | Date | Value |
|---|---|---|
| PE Ratio | - | |
| PS Ratio | - | |
| PB Ratio | 12.68 | |
| EV/EBITDA | -30.67 | |
| Enterprise Value | N/A | - |
Balance Sheet
| Metric | Date | Value |
|---|---|---|
| Book Value | $345.87M | |
| Cash & Equivalents | $161.44M | |
| Total Assets | $363.93M | |
| Current Assets | $362.11M | |
| Total Liabilities | $18.06M | |
| Current Liabilities | $15.65M | |
| Total Debt | $1.35M | |
| Short Term Debt | $428.00K | |
| Accounts Payable | $2.15M |
Expenses
| Metric | Date | Value |
|---|---|---|
| Total Expenses | $101.87M | |
| Operating Expenses | $101.87M | |
| Cost Of Goods Sold | $896.00K | |
| SG&A | $31.76M | |
| D&A | $896.00K | |
| Interest Expense | $0.00 | |
| Income Tax | $260.00K |
Cash Flow
| Metric | Date | Value |
|---|---|---|
| CFO | -$70.02M | |
| CFI | -$12.41M | |
| CFF | $164.00M | |
| Capex | $42.00K | |
| Free Cash Flow | -$70.06M |
Recent analyst updates
| Metric | Date | Value |
|---|---|---|
| Citizens | → | |
| Truist Securities | → | |
| Oppenheimer | → | |
| Mizuho | → | |
| HC Wainwright & Co. | → | |
| Barclays | → | |
| BMO Capital | → | |
| Citizens | → | |
| Barclays | → | |
| Truist Securities | → |
Analyst sentiment
Institutional ownership
Screeners with TERN
Data Sources & References
- TERN Official Website www.ternspharma.com
- Most Recent Quarterly Report (10-Q) www.sec.gov/Archives/edgar/data/1831363/000119312525274367/0001193125-25-274367-index.htm
- Most Recent Annual Report (10-K) www.sec.gov/Archives/edgar/data/1831363/000095017025042695/0000950170-25-042695-index.htm
- TERN Profile on Yahoo Finance finance.yahoo.com/quote/TERN
- TERN Profile on NASDAQ.com www.nasdaq.com/market-activity/stocks/tern
FAQ
What is the ticker symbol for Terns Pharmaceuticals, Inc.?
The ticker symbol for Terns Pharmaceuticals, Inc. is NASDAQ:TERN
Does Terns Pharmaceuticals, Inc. pay dividends?
No, Terns Pharmaceuticals, Inc. does not pay dividends
What sector is Terns Pharmaceuticals, Inc. in?
Terns Pharmaceuticals, Inc. is in the Healthcare sector
What industry is Terns Pharmaceuticals, Inc. in?
Terns Pharmaceuticals, Inc. is in the Biotechnology industry
What country is Terns Pharmaceuticals, Inc. based in?
Terns Pharmaceuticals, Inc. is headquartered in United States
When did Terns Pharmaceuticals, Inc. go public?
Terns Pharmaceuticals, Inc. initial public offering (IPO) was on February 5, 2021
Is Terns Pharmaceuticals, Inc. in the S&P 500?
No, Terns Pharmaceuticals, Inc. is not included in the S&P 500 index
Is Terns Pharmaceuticals, Inc. in the NASDAQ 100?
No, Terns Pharmaceuticals, Inc. is not included in the NASDAQ 100 index
Is Terns Pharmaceuticals, Inc. in the Dow Jones?
No, Terns Pharmaceuticals, Inc. is not included in the Dow Jones index
When was Terns Pharmaceuticals, Inc. last earnings report?
Terns Pharmaceuticals, Inc.'s most recent earnings report was on November 12, 2025
When does Terns Pharmaceuticals, Inc. report earnings?
The date for Terns Pharmaceuticals, Inc.'s next earnings report has not been announced yet